Recent Updates
Recently added Catalysts
TMDX Negative Sentiment

TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating TransMedics Group, Inc. regarding potential violations of federal securities laws on behalf of its stockholders. The investigation follows a report from Scorpion Capital alleging that TransMedics is engaged in serious fraudulent practices, particularly in relation to the treatment of terminally ill patients. The firm encourages affected investors to reach out to discuss their rights and possible claims.
Price reaction · baseline $60.44 (2025-01-15 close) · hit after-hours · 5 other TMDX headline(s) in the window, move may be shared
day 0 close · peak
-4%

Market Sentiment Analysis

CONCERNS & RISKS

  • TransMedics is under investigation for potential violations of federal securities laws.
  • A report claims that TransMedics is involved in extreme healthcare fraud targeting vulnerable patients.
  • Allegations include issuing misleading statements and failing to disclose critical information to investors.

Full Press Release Details

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) on behalf of TransMedics stockholders. Our investigation concerns whether TransMedics has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. TransMedics is the subject of a report issued by Scorpion Capital on January 10, 2025. The report claims that in “20 years of shorting, TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients – the terminally ill, desperate for an organ. The ‘lucky’ patients who receive a diseased, damaged organ rejected by reputable surgeons and centers … are oblivious to the cesspool of perverse, secret incentives that steered the organ their way.”
If you purchased or otherwise acquired TransMedics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the purpose of the Bragar Eagel & Squire investigation?

The investigation aims to explore potential claims against TransMedics for violating securities laws.

What concerns were raised about TransMedics?

Concerns include misinformation and undisclosed details that could impact investors.

What does the Scorpion Capital report allege?

It alleges TransMedics represents extreme healthcare fraud targeting vulnerable patients.

How can TransMedics stockholders participate in the investigation?

Stockholders can contact the law firm via email or phone to learn how to participate.

What services does Bragar Eagel & Squire provide?

The firm represents investors in complex litigation, including securities and commercial matters.

Last updated: Jan 16, 2025